In the current study, scientists generate and analyze genomic, transcriptomic, and T-cell receptor sequencing data of metastatic PDAC patients to explore molecular and immune differences between ...
New research uncovers how distinct molecular profiles and immune signatures in ... the prognosis of patients with metastatic pancreatic ductal adenocarcinoma (PDAC). PDAC is a highly aggressive ...
Surufatinib plus TAS-102 showed promising survival benefits with manageable toxicity in refractory metastatic PDAC patients, per phase 2 trial data. Data from a phase 2 trial (NCT05481463) presented ...
Safety of these combination therapies will continue to be monitored.” Although only a small subset of patients with metastatic PDAC who have microsatellite instability–high or mismatch ...
Background: Patients with pancreatic ductal adenocarcinoma (PDAC) face a highly unfavorable outcome and have a poor response to standard treatments. Immunotherapy, especially therapy based on natural ...
Jan. 28, 2025 — Study reveals how immune cells in the gut distinguish between food and harmful pathogens, shedding light on the origins of both food allergies and intestinal ...
in PDAC. The difference is significant (p < 0.001). (B) boxplots depicting K102-Env levels for 24 patients with distant metastases (M1) and 23 patients without distant metastases (M0) in HCC. The ...